

XOSPATA®

Active ingredient(s): gilteritinib (as fumarate)

Consumer Medicine Information

This leaflet answers some common questions about XOSPATA.

It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the risks of you taking XOSPATA against the benefits they expect it will have for you.

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

Keep this leaflet with the medicine.

You may need to read it again.

Where to find information in this leaflet:

1. Why am I using XOSPATA?
2. What should I know before I use XOSPATA?
3. What if I am taking other medicines?
4. How do I use XOSPATA?
5. What should I know while taking XOSPATA?
6. Are there any side effects?
7. Product details

AML is a form of cancer of certain white blood cells (called myeloid cells). This medicine works by blocking the action of certain enzymes (kinases) in the abnormal cells. By blocking kinases, XOSPATA stops the cancer cells from growing and dividing.

Ask your doctor if you have any questions about why this medicine has been prescribed for you.

Your doctor may have prescribed it for another reason.

XOSPATA is not for use in children and adolescents.

Safety and effectiveness in children and adolescents have not been established.

1. Why am I using XOSPATA?

XOSPATA contains gilteritinib, a protein kinase inhibitor, which is used to treat adults with acute myeloid leukaemia (AML) who have a defect in a gene called FLT3 when the disease has come back or has not improved after previous treatment(s).